Pharmacologic inhibition of GSK-3 decreases NFκB-mediated survival of CLL cells. Malignant B cells from 11 patients with CLL were treated with diluent (DMSO) or 25 μmol/L AR-A014418; at the indicated time after treatment, the cell pellet was collected and protein was obtained. Cell lysates were separated by SDS-PAGE, transferred to PVDF membrane, and immunoblotted with the indicated antibodies. Western blot band intensities were quantified by using the Image J software (National Institutes of Health). The quantitative analysis of Bcl-2 protein levels (normalized to β-actin levels in each case) in DMSO versus AR-A014418–treated CLL B cells obtained from 11 patients with CLL are presented in the lower panel. ARA indicates AR-A014418; P, patient.